{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:32:34Z","timestamp":1772253154248,"version":"3.50.1"},"reference-count":20,"publisher":"Sociedade Brasileira de Cardiologia","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Bras. Cardiol."],"abstract":"<jats:p>Resumo  Fundamento  Recentemente, foi demonstrado que o alopurinol, um inibidor da xantina oxidase, possui propriedades cardiovasculares e anti-isqu\u00eamicas e pode ser uma op\u00e7\u00e3o de agente antianginoso metab\u00f3lico.  Objetivo  O objetivo do presente estudo foi avaliar o efeito antianginoso do alopurinol como terceiro medicamento para pacientes com doen\u00e7a arterial coronariana (DAC) est\u00e1vel.  M\u00e9todos  Trata-se de um ensaio cl\u00ednico randomizado entre 2018 e 2020 incluindo pacientes com DAC que mantiveram angina apesar da otimiza\u00e7\u00e3o inicial com betabloqueadores e bloqueadores dos canais de c\u00e1lcio. Os indiv\u00edduos foram randomizados 1:1 para 300 mg de alopurinol 2 vezes ao dia ou 35 mg de trimetazidina 2 vezes ao dia. O desfecho principal foi a diferen\u00e7a no dom\u00ednio da frequ\u00eancia da angina do Question\u00e1rio de Angina de Seattle (QAS-FA). Foram considerados estatisticamente significativos valores de probabilidade (p) &lt; 0,05.  Resultados  Foram inclu\u00eddos 108 pacientes na fase de randomiza\u00e7\u00e3o, com 54 (50%) no grupo alopurinol e 54 (50%) no grupo trimetazidina. Seis (5,6%) indiv\u00edduos, 3 de cada grupo, foram perdidos no seguimento para o desfecho prim\u00e1rio. Nos grupos de alopurinol e trimetazidina, as pontua\u00e7\u00f5es medianas do QAS-FA foram 50 (30,0 a 70,0) e 50 (21,3 a 78,3), respectivamente. Em ambos os grupos, a pontua\u00e7\u00e3o do QAS-FA melhorou, mas a mediana da diferen\u00e7a em rela\u00e7\u00e3o \u00e0 linha de base foi menor no grupo alopurinol (10 [0 a 30] versus 20 [10 a 40]; p &lt; 0,001), assim como a m\u00e9dia da diferen\u00e7a na pontua\u00e7\u00e3o total do QAS (12,8 \u00b1 17,8 versus 21,2 \u00b1 15,9; p = 0,014).  Conclus\u00e3o  Tanto o alopurinol quanto a trimetazidina melhoraram o controle dos sintomas de angina; no entanto, a trimetazidina apresentou um ganho maior em rela\u00e7\u00e3o \u00e0 linha de base. Registro Brasileiro de Ensaios Cl\u00ednicos \u2013 N\u00famero de Registro RBR-5kh98y<\/jats:p>","DOI":"10.36660\/abc.20230659","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T11:59:24Z","timestamp":1724846364000},"source":"Crossref","is-referenced-by-count":0,"title":["Alopurinol Versus Trimetazidina para o Tratamento da Angina: Ensaio Cl\u00ednico Randomizado"],"prefix":"10.36660","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1194-8246","authenticated-orcid":false,"given":"Tain\u00e1","family":"Viana","sequence":"first","affiliation":[{"name":"Universidade Federal da Bahia,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo Morel Vieira de","family":"Melo","sequence":"additional","affiliation":[{"name":"Universidade Federal da Bahia,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diogo Freitas Cardoso","family":"Azevedo","sequence":"additional","affiliation":[{"name":"Ana Nery Hospital,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7722-9087","authenticated-orcid":false,"given":"Clara Salles","family":"Figueiredo","sequence":"additional","affiliation":[{"name":"Universidade Federal da Bahia,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Santana","sequence":"additional","affiliation":[{"name":"Universidade Federal da Bahia,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3700-4924","authenticated-orcid":false,"given":"Luanna Mota","family":"Damasceno","sequence":"additional","affiliation":[{"name":"Ana Nery Hospital,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4076-7796","authenticated-orcid":false,"given":"Luisa","family":"Latado","sequence":"additional","affiliation":[{"name":"Ana Nery Hospital,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludmila","family":"Tambuque","sequence":"additional","affiliation":[{"name":"Ana Nery Hospital,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raissa","family":"Barreto","sequence":"additional","affiliation":[{"name":"Ana Nery Hospital,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz Carlos Santana","family":"Passos","sequence":"additional","affiliation":[{"name":"Ana Nery Hospital,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22636","published-online":{"date-parts":[[2024,8]]},"reference":[{"issue":"15","key":"ref1","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"Optimal Medical Therapy with or Without PCI for Stable Coronary Disease","volume":"356","author":"Boden WE","year":"2007","journal-title":"N Engl J Med"},{"issue":"15","key":"ref2","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1915922","article-title":"Initial Invasive or Conservative Strategy for Stable Coronary Disease","volume":"382","author":"Maron DJ","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes","volume":"41","author":"Knuuti J","year":"2020","journal-title":"Eur Heart J"},{"issue":"8","key":"ref4","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jacc.2010.12.052","article-title":"Mechanistic Insights into the Therapeutic Use of High-dose Allopurinol in Angina Pectoris","volume":"58","author":"Rajendra NS","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"ref5","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1136\/heartjnl-2014-305683","article-title":"Allopurinol Reduces Brachial and Central Blood Pressure, and Carotid Intima-media Thickness Progression after Ischaemic Stroke and Transient Ischaemic Attack: A Randomised Controlled Trial","volume":"100","author":"Higgins P","year":"2014","journal-title":"Heart"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/FJC.0000000000000409","article-title":"The Impact of Allopurinol on Patients with Acute ST Elevation Myocardial Infarction Undergoing Thrombolytic Therapy","volume":"68","author":"Separham A","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1161\/01.CIR.0000022140.61460.1D","article-title":"Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure","volume":"106","author":"Farquharson CA","year":"2002","journal-title":"Circulation"},{"issue":"9732","key":"ref8","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(10)60391-1","article-title":"Effect of High-dose Allopurinol on Exercise in Patients with Chronic Stable Angina: A Randomised, Placebo Controlled Crossover Trial","volume":"375","author":"Noman A","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0735-1097(94)00397-9","article-title":"Development and Evaluation of the Seattle Angina Questionnaire: A New Functional Status Measure for Coronary Artery Disease","volume":"25","author":"Spertus JA","year":"1995","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"ref10","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1161\/CIRCOUTCOMES.113.000752","article-title":"Comparison of the Seattle Angina Questionnaire with Daily Angina Diary in the TERISA Clinical Trial","volume":"7","author":"Arnold SV","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/eurheartj\/ehy504","article-title":"Anti-anginal Drugs-Beliefs and Evidence: Systematic Review Covering 50 Years of Medical Treatment","volume":"40","author":"Ferrari R","year":"2019","journal-title":"Eur Heart J"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/nrcardio.2017.131","article-title":"Expert Consensus Document: A 'Diamond' Approach to Personalized Treatment of Angina","volume":"15","author":"Ferrari R","year":"2018","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/1479164109354145","article-title":"The BARI 2D Study: A Randomised Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease","volume":"7","author":"Rutter MK","year":"2010","journal-title":"Diab Vasc Dis Res"},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1089\/jwh.2018.7019","article-title":"Ranolazine Reduces Angina in Women with Ischemic Heart Disease: Results of an Open-Label, Multicenter Trial","volume":"28","author":"Mehta PK","year":"2019","journal-title":"J Womens Health"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40256-016-0168-1","article-title":"Anti-Anginal and Metabolic Effects of Carvedilol and Atenolol in Patients with Stable Angina Pectoris: A Prospective, Randomized, Parallel, Open-Label Study","volume":"16","author":"Oh PC","year":"2016","journal-title":"Am J Cardiovasc Drugs"},{"issue":"26","key":"ref16","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1093\/eurheartj\/ehy220","article-title":"A Randomized Multicentre Trial to Compare Revascularization with Optimal Medical Therapy for the Treatment of Chronic Total Coronary Occlusions","volume":"39","author":"Werner GS","year":"2018","journal-title":"Eur Heart J"},{"issue":"10115","key":"ref17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(17)32714-9","article-title":"Percutaneous Coronary Intervention in Stable Angina (ORBITA): A Double-blind, Randomised Controlled Trial","volume":"391","author":"Al-Lamee R","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"ref18","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0895-4356(98)00028-6","article-title":"Comparison of Three Quality of Life Instruments in Stable Angina Pectoris: Seattle Angina Questionnaire, Short Form Health Survey (SF-36), and Quality of Life Index-Cardiac Version III","volume":"51","author":"Dougherty CM","year":"1998","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s11136-005-5993-7","article-title":"Responsiveness of the Coronary Revascularisation Outcome Questionnaire Compared with the SF-36 and Seattle Angina Questionnaire","volume":"15","author":"Schroter S","year":"2006","journal-title":"Qual Life Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2147\/TCRM.S82288","article-title":"Ranolazine versus Placebo in Patients with Ischemic Cardiomyopathy and Persistent Chest Pain or Dyspnea Despite Optimal Medical and Revascularization Therapy: Randomized, Double-blind Crossover Pilot Study","volume":"11","author":"Shammas NW","year":"2015","journal-title":"Ther Clin Risk Manag"}],"container-title":["Arquivos Brasileiros de Cardiologia"],"original-title":["Allopurinol versus Trimetazidine for the Treatment of Angina: A Randomized Clinical Trial"],"link":[{"URL":"https:\/\/abccardiol.org\/wp-content\/uploads\/articles_xml\/0066-782X-abc-121-8-e20230659\/0066-782X-abc-121-8-e20230659.x47225.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T11:59:37Z","timestamp":1724846377000},"score":1,"resource":{"primary":{"URL":"https:\/\/abccardiol.org\/article\/alopurinol-versus-trimetazidina-para-o-tratamento-da-angina-ensaio-clinico-randomizado\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["S0066-782X2024000800302"],"URL":"https:\/\/doi.org\/10.36660\/abc.20230659","relation":{"is-translation-of":[{"id-type":"doi","id":"10.36660\/abc.20230659i","asserted-by":"subject"},{"id-type":"doi","id":"10.36660\/abc.20230659i","asserted-by":"object"}]},"ISSN":["1678-4170","0066-782X"],"issn-type":[{"value":"1678-4170","type":"electronic"},{"value":"0066-782X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"article-number":"e20230659"}}